作者: M VANHOEF
DOI: 10.1016/0300-2977(95)00109-3
关键词: Progenitor cell 、 Internal medicine 、 Immunology 、 Oncology 、 CD34 、 Medicine 、 Leukapheresis 、 Mobilization 、 Transplantation 、 Chemotherapy 、 Stem cell 、 Haematopoiesis
摘要: Abstract In recent years peripheral blood progenitor cells (PBPC) have increasingly been used to support hematological recovery after high-dose chemotherapy treatment. PBPC are collected by leukopheresis mobilization and/or hematopoietic growth factors. Efficient and correct timing of is essential minimize the number leukophereses required for collection sufficient transplantation. Mobilization efficiency influenced various factors recruitment can be assessed cell assays FACS analysis. Target values rapid reconstitution reported, but threshold conditions still need established. CD34 + selection value tumor purging may important reduction relapse rate solid tumors malignancies.